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We report the discovery of novel boron-containing molecules, exemplified by N-(1-hydroxy-1,3-
dihydrobenzo[c][1,2]oxaborol-6-yl)-2-trifluoromethylbenzamide (AN3520) and 4-fluoro-N-(1-hydroxy-1,3-
dihydrobenzo[c][1,2]oxaborol-6-yl)-2-trifluoromethylbenzamide (SCYX-6759), as potent compounds
against Trypanosoma brucei in vitro, including the two subspecies responsible for human disease T. b.
rhodesiense and T. b. gambiense. These oxaborole carboxamides cured stage 1 (hemolymphatic) trypano-
somiasis infection in mice when administered orally at 2.5 to 10 mg/kg of body weight for 4 consecutive
days. In stage 2 disease (central nervous system [CNS] involvement), mice infected with T. b. brucei were
cured when AN3520 or SCYX-6759 were administered intraperitoneally or orally (50 mg/kg) twice daily for
7 days. Oxaborole-treated animals did not exhibit gross signs of compound-related acute or subchronic
toxicity. Metabolism and pharmacokinetic studies in several species, including nonhuman primates,
demonstrate that both SCYX-6759 and AN3520 are low-clearance compounds. Both compounds were well
absorbed following oral dosing in multiple species and also demonstrated the ability to cross the blood-
brain barrier with no evidence of interaction with the P-glycoprotein transporter. Overall, SCYX-6759
demonstrated superior pharmacokinetics, and this was reflected in better efficacy against stage 2 disease
in the mouse model. On the whole, oxaboroles demonstrate potent activity against all T. brucei subspecies,
excellent physicochemical profiles, in vitro metabolic stability, a low potential for CYP450 inhibition, a
lack of active efflux by the P-glycoprotein transporter, and high permeability. These properties strongly
suggest that these novel chemical entities are suitable leads for the development of new and effective orally
administered treatments for human African trypanosomiasis.
Human African trypanosomiasis (HAT), perhaps better
known as sleeping sickness, is a major threat to the health of
over 60 million people in 36 countries in sub-Saharan Africa
(11). The estimated number of cases is 50,000 to 70,000 (38,
44). Sleeping sickness is caused by the trypanosomatid proto-
zoan parasite Trypanosoma brucei and is spread by the bite of
a tsetse fly. If left untreated, HAT is inevitably fatal (22). There
are two main subspecies, T. b. rhodesiense (East Africa) and T.
b. gambiense (West Africa), which result in human disease.
Currently, treatment is limited to four drugs which are highly
toxic and complicated to administer and require lengthy treat-
ment regimens (23, 44). Treatment for stage 1, when the par-
asites are limited to the hemolymphatic system, is administra-
tion of pentamidine (T. b. gambiense) or suramin (T. b.
rhodesiense). In stage 2, or central nervous system (CNS) dis-
ease, either melarsoprol (T. b. gambiense and T. b. rhodesiense)
or eflornithine (T. b. gambiense) is used (14). Melarsoprol kills
5 to 10% of patients (32), and treatment failures of up to 25%
have been reported (12, 13). Difluoromethylornithine
(DFMO) (Ornidyl) requires a 2-week therapy regimen which is
difficult to administer in rural clinics (34). A new combination
therapy with DFMO and oral nifurtimox (NECT) reduces the
dose time to 1 week but still requires intravenous (i.v.) dosing
(35).
Antigenic variation is frequent, rendering prospects for vac-
cine development impracticable (22, 27). What is urgently
needed is a safe, orally (p.o.) administered drug, effective
against both stages 1 and 2 of HAT, which then eliminates the
need for staging and raises the potential for the eradication of
sleeping sickness. Toward this aspiration, we have identified a
class of boron-containing compounds, oxaborole carboxam-
ides, as novel leads that show potent and selective trypanocidal
activity in vitro. Two examples chosen from this lead series are
AN3520 and SCYX-6759. These compounds exhibit rapid,
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time-dependent cidal activity against T. brucei in vitro and in
vivo and are curative in mice with acute or neurological forms
of the disease. These oxaborole carboxamides are highly per-
meable and metabolically stable. Pharmacokinetic analysis
demonstrates that AN3520 and SCYX-6759 are orally bioavail-
able and are able to cross the blood-brain barrier (BBB) at
sufficient levels to cure mice in stage 2 of disease. Development
of oxaborole carboxamides represents the first time within the
past 30 years that a novel lead compound class with activity
against the CNS disease model has been identified.
MATERIALS AND METHODS
Test compounds. A library of proprietary small molecule therapeutics de-
rived from a boron chemistry platform provides the basis for this drug dis-
covery effort. This library of oxaborole compounds was jointly screened by
Anacor Pharmaceuticals, Inc. (Palo Alto, CA) and Scynexis, Inc. (Research
Triangle Park, NC). Additional analogues were synthesized in-house (Scyn-
exis, Inc., Research Triangle Park, NC) during lead optimization. AN3520
[N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-2-trifluoromethylbenzamide] and
SCYX-6759 [4-fluoro-N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-2-trifluoro-
methylbenzamide] are representative oxaborole 6-carboxamides that demonstrate
potent activity against Trypanosoma brucei, including the clinically relevant
subspecies T. b. rhodesiense and T. b. gambiense. AN3520 and SCYX-6759
were prepared as 10-mg/ml stocks in dimethyl sulfoxide (DMSO) for in vitro
biological and absorption, distribution, metabolism, and excretion (ADME)
assays. All compounds were synthesized to a purity of more than 95%, and
their identities were confirmed by proton nuclear magnetic resonance (NMR)
and high-pressure liquid chromatography (HPLC) with mass spectrometry.
Trypanosome and cell culture. The bloodstream form T. brucei brucei 427
strain was obtained from Ken Stuart (Seattle Biomedical Research Institute,
Seattle, WA) and was used for routine assessment of compound sensitivity in
vitro. Additional strains used in vitro include T. b. rhodesiense STIB900 and T. b.
gambiense STIB930, a derivative of strain THI/78E (031). T. b. brucei EATRO
110 was a generous gift from the late William Trager of Rockefeller University.
The T. b. brucei TREU 667 strain was kindly provided by F. W. Jennings at the
University of Glasgow. Both T. b. brucei EATRO 110 and TREU 667 were
cultured according to previously described conditions (19, 42) and used for in
vivo studies.
T. b. brucei was cultured in complete HMI-9 medium (17) with 10% fetal
bovine serum (FBS) (Invitrogen, Carlsbad, CA), 10% Serum Plus medium
(SAFC Biosciences, Lenexa, KS), and 100 units/ml penicillin and 0.1 mg/ml
streptomycin. To ensure log growth phase, trypanosomes were subcultured at the
appropriate dilutions (typically 1:100) every 2 to 3 days in fresh HMI-9 medium.
T. b. rhodesiense parasites were grown in minimum essential medium (MEM)
with Earle’s salts supplemented with 15% horse serum. For T. b. gambiense, the
MEM was supplemented with 5% heat-inactivated fetal calf serum (FCS) and
15% human serum (8). L929 mouse fibroblast cells (ATCC CCL1; American
Type Culture Collection, Rockville, MD) were used to determine parasite versus
mammalian cell selectivity. MDCKII-hMDR1 cells were generously provided by
Pieter Borst at the Netherlands Cancer Institute. Mammalian cells were cultured
in Dulbecco’s modified Eagle medium (DMEM) containing 10% (vol/vol) FBS,
100 units/ml penicillin, and 0.1 mg/ml streptomycin, and Glutamax was added to
MDCKII-hMDR1 cultures.
In vitro compound sensitivity assays. Compounds to be tested were serially
diluted in DMSO and added to 96-well plates to give final concentrations ranging
from 0.01 to 5 g/ml. T. b. brucei parasites in the log phase of growth were diluted
in HMI-9 medium and added to each well for a final concentration of 1  104
parasites per well. For the sensitivity assays using T. b. rhodesiense and T. b.
gambiense, parasites were cultured in MEM supplemented with Baltz compo-
nents (8), diluted in the aforementioned culture medium, and added to each well
at a density of 1  103 cells/well. The final concentration of DMSO was 0.5%.
After 72 h of incubation, resazurin (Sigma-Aldrich, St. Louis, MO) (36) was
added to each well (20 l of 25-mg/100-ml stock in phosphate buffered saline
[PBS]) and incubated for an additional 4 to 6 h. To assess cell viability, fluores-
cence was quantified using an EnVision multilabel plate reader (Perkin Elmer,
Waltham, MA) at an excitation wavelength of 530 nm and an emission of 590 nm.
Triplicate data points were averaged to generate sigmoidal dose response curves
and determine 50% inhibitory concentration (IC50) or IC90 values using XLfit
curve-fitting software from IDBS (Guilford, United Kingdom). The IC50 is de-
fined as the amount of compound required to decrease parasite or cell viability
by 50% compared to the number of parasites grown in the absence of the test
compound. The MIC, defined as the lowest concentration of a compound that
completely inhibits visible parasite growth, was determined by visual inspection
of 96-well plates after 48 to 72 h of incubation with the test compounds. To
evaluate the effects of serum on trypanocidal activity, assays were performed in
the presence of increasing concentrations of FCS (Invitrogen, Carlsbad, CA),
from 2.5 to 50%. The results were expressed as fold changes in IC50s relative to
standard conditions (10% FCS).
An evaluation of mammalian cell cytotoxicity was carried out in parallel with
the trypanosome sensitivity assays. L929 mouse fibroblast cells were seeded at
2  103 per well and handled as described above for the trypanosome sensitivity
assay.
Time-kill assays. The assessment of oxaborole-mediated killing of T. b. brucei
in vitro was conducted using the CellTiter Glo kit (Promega, Inc., Madison, WI)
to measure trypanosome ATP content as a real-time indicator of viability. Test
compounds were serially diluted from 5 to 0.01 g/ml into white-wall/clear-
bottom 96-well plates (Corning Inc., Lowell, MA) containing HMI-9 media.
Trypanosomes (1  104) were added to each well. At specified intervals, the
CellTiter Glo reagent was added to lyse the parasites, and the plates were
incubated for 10 min in the dark. Luminescence was quantified using an EnVi-
sion plate reader. All determinations were done in duplicate. Time-kill param-
eters were determined from plots of parasite viability versus incubation time for
each concentration tested. To study drug-induced morphological changes,
treated parasites were observed under the 100 objective on a Nikon TE2000
equipped with a DS-Di1 cooled monochrome camera and NIS-Elements imaging
software (Nikon Instruments, Lewisville, TX). Several microscope fields were
observed, and drug effects on parasites from each of the test concentrations were
documented.
Examination of reversibility of trypanocidal effects. To establish the time
required to cause persistent or irreversible effects by oxaboroles, T. b. brucei
parasites were assessed for their ability to recover from transient exposure to test
compounds. Trypanosomes were seeded in clear 96-well V-bottom plates at a
density of 1  105 parasites per well and incubated with the serially diluted test
compound (from 0.02 to 10 g/ml). One plate was prepared for each time point.
At the designated time, a plate was removed from the incubator and spun at
4.4  103 rpm for 5 min to sediment the parasites. The supernatant was aspi-
rated, and 100 l of warmed HMI-9 medium was added to each well. The wash
was repeated twice more. The parasites were resuspended in 100 l of warmed
medium, and 20 l of this suspension was added to 80 l of HMI-9 medium in
triplicate plates. Following 72 h of incubation, resazurin was added and trypano-
cidal activity determined as described for the in vitro sensitivity assay.
Efficacy in the mouse model for acute HAT. For efficacy studies against acute
infections, groups of 3 to 5 female Swiss Webster mice (Ace Animals, Boyertown,
PA) were injected intraperitoneally (i.p.) with freshly drawn infected rat blood
containing 2.5  105 trypanosomes (T. b. brucei EATRO 110 strain). Oxaborole
compounds were formulated in 2% ethanol-5% dextrose and were given at a
dose volume of 200 l for a 25-g animal starting 24 h after infection. Animals
remaining parasite free for more than 30 days beyond the end of the treat-
ment period were considered cured (3, 4).
Efficacy in a mouse model for chronic (CNS) HAT. Evaluation of AN3520 and
SCYX6759 against stage 2 CNS infections was conducted with a chronic disease-
inducing strain (TREU 667) of T. b. brucei (3, 4, 5). Female Swiss Webster mice
were infected intraperitoneally with 1  104 parasites (200 l) followed by
treatment with a single 10 mg/kg i.p. dose of diminazene aceturate (Berenil) on
day 4 postinfection to serve as the positive control. Infection in the remaining
groups of animals was allowed to proceed for 21 days prior to treatment with
either diminazene aceturate (single i.p. dose at 10 mg/kg) or the test compound
given i.p. or p.o. twice daily for 7 or 14 days. Animals were immediately removed
from the cages and euthanized upon recrudescence. Animals remaining apara-
sitemic for at least 180 days after the end of the treatment period were consid-
ered cured (3, 4, 5). Brain homogenates or the blood of oxaborole-cured animals
failed to generate infection when injected into naive, cyclophosphamide-immu-
nosuppressed mice.
Plasma protein and brain tissue binding. Binding of AN3520 and SCYX-6759
to human or mouse plasma proteins or mouse brain homogenate was determined
by rapid equilibrium dialysis (RED) (Pierce, Rockford, IL) using a 48-well-plate-
based format according to the manufacturer’s instructions. Briefly, 0.5, 2.0, or 5.0
M AN3520 and SCYX-6759 was added to fresh human or mouse plasma
(Bioreclamation, Liverpool, NY) or mouse brain homogenate. Duplicate ali-
quots of each plasma or brain sample were transferred into the sample chambers
of the RED devices, and dialysis buffer (BupH PBS) was added to the buffer
chambers. The plates were sealed and incubated at 37°C for 4 h. After dialysis,
samples collected from the buffer and tissue chambers were treated with ice-cold
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methanol (3 volumes for plasma, 4 volumes for brain) to precipitate proteins.
The treated samples were centrifuged for 10 min at 3,000  g at 15°C. The
supernatants were assayed for the test compound by liquid chromatography-
tandem mass spectrometry (LC-MS/MS). Calibration standards and quality-
control samples were prepared in a matched matrix and assayed with samples.
Values for unbound and bound fractions and mass balance were calculated.
Concordance of binding for each batch of plasma was confirmed by assay of
warfarin, imipramine, and carbamazepine.
In vitro metabolism. The metabolic stability of AN3520 and SCYX-6759 was
evaluated using CD-1 mouse or human liver microsomal fractions (from males
and females) (XenoTech, Lenexa, KS). The method was adapted from a previ-
ously published procedure (25). Briefly, AN3520 and SCYX-6759 (1 M) were
incubated with microsomes (1.05 mg/ml protein) for 0, 10, 15, and 30 min at 37°C
in an oxygen-enriched environment in the presence of an NADPH-regenerating
system. Each compound was also incubated, under similar conditions, but with
uridine-5 diphosphoglucoronosyltransferase and liver S9 subcellular fractions
from various species (2.5 mg/ml protein) (10) for 0, 15, 30, and 60 min. The
reactions were quenched with 3 volumes of ice-cold methanol, and supernatants
were analyzed for the parent compound by LC-MS/MS. Metabolic competencies
of microsomal and S9 fractions were confirmed using control compounds
7-ethoxycoumarin, propranolol, and verapamil. Intrinsic clearance (CLint) and/or
half-life (t1/2) values were determined for each compound.
In vitro prediction of BBB permeability and P-glycoprotein (P-gp)-mediated
efflux transport. The propensity for AN3520 and SCYX-6759 to cross the blood-
brain barrier (BBB) was examined using an in vitro MDCKII-hMDR1 Transwell
assay (33). MDCKII-hMDR1 cells were seeded at a density of 3  105 cells per
well onto microporous polycarbonate membranes in 12-well Costar Transwell
plates (Corning Inc., Lowell, MA). The cells were used for permeability studies
3 days later. Trans-epithelial resistance (TEER) was measured for each insert to
ensure the integrity of the monolayer (acceptable TEER values were50cm2).
The permeability and propensity for P-gp-mediated efflux of AN3520 and
SCYX-6759 were evaluated by adding each compound at a concentration of 3
M, in the presence or absence of 2 M GF120918, to the apical compartment.
Competency of the P-gp efflux transporter was confirmed by assay of propranolol
(nonsubstrate) and amprenavir (substrate). Cell monolayers were incubated in
triplicate with shaking (160 rpm) at 37°C in a 5% CO2-enriched humidified
atmosphere for 1 h. Samples were removed from the apical and basolateral
compartments after incubation and assayed for test compound concentrations by
LC-MS/MS. Values for mass balance, PappA3B (apparent permeability value in
nm/s for the apical to the basolateral direction), PappA3BGF918 (apparent
permeability value in nm/s for the apical to the basolateral direction in the
presence of an MDR1 [Pgp] inhibitor), and absorption quotient (AQ) (40, 41,
43) were calculated for each compound. Acceptance criterion for mass balance
was 70 to 120%.
In vitro stability in mouse brain homogenate. The stability of each oxaborole
in CNS tissue was evaluated by incubation in fresh rodent brain homogenate.
AN3520 and SCYX-6759 (0.1 M or 5 M) were incubated in freshly prepared
homogenates of mouse brain tissue for 5 h at 37°C with gentle shaking. After
incubation, the reactions were quenched with 4 volumes of ice-cold methanol.
Supernatants from the incubation mixtures were analyzed for the parent com-
pound by LC-MS/MS.
In vitro inhibition of cytochrome P450 enzymes. The potential for AN3520 and
SCYX-6759 to exert drug-drug interactions which are mediated through inhibi-
tion of cytochrome P450 activities was assessed using P450-Glo assay kits (Pro-
mega Inc., Madison, WI). Assays for human cytochrome P450 isoforms 3A4,
1A2, 2C9, 2C19, and 2D6 were performed in triplicate according to the manu-
facturer’s instructions for the concentration range 1 to 100 M (6 levels). Briefly,
AN3520 and SCYX-6759 were added to membrane preparations containing
human recombinant CYP450 enzymes together with luminogenic substrates spe-
cific to each isoform. Specific CYP450 inhibitors were included as positive con-
trols (ketoconazole, CYP3A4; alpha-naphthoflavone, 1A2; sulfaphenazole,
CYP2C9; troglitazone, 2C19; and quinidine, CYP2D6). Reactions were initiated
by the addition of NADPH-regenerating solution and were allowed to incubate
an additional 15 to 30 min (isoform dependent). Luciferin detection reagent,
containing the luciferin-labeled probe substrate, was then added. Luminescence
was recorded on an EnVision multilabel plate reader. Calculation of IC50s for
each enzyme was determined using GraphPad Prism (V5.01). The potential for
drug-drug interactions was characterized as high (IC50  1 M), moderate (1
M  IC50  10 M), or low (IC50  10 M) (25).
Pharmacokinetic studies in rodents and nonhuman primates. The blood dis-
tribution, CNS disposition, and pharmacokinetics of AN3520 and SCYX-6759
were evaluated in infected or noninfected rodents following intravenous or oral
administration of compounds. Pharmacokinetics and bioavailability of SCYX-
6759 were also evaluated in noninfected cynomolgus monkeys. All rodent pro-
cedures were performed following Institutional Animal Care and Use Commit-
tee (IACUC) review and in Association for Assessment and Accreditation of
Laboratory Animal Care International (AAALAC)-approved facilities. In vivo
phases of rodent studies were performed at ViviSource (Waltham, MA); studies
in nonnaïve cynomolgus monkeys were performed by BioDuro (Beijing, China).
Male CD-1 mice (approximately 25 g), male Sprague-Dawley rats (approxi-
mately 225 g), or male cynomolgus monkeys (approximately 3 to 5 kg) were
administered the test article by either bolus intravenous injection or oral gavage.
Animals in the i.v. groups received a single 2-mg/kg i.v. dose. Animals received
oral doses of the test articles either once or twice daily, with doses ranging from
8 mg/kg to 50 mg/kg. All doses were administered as clear colorless solutions in
either 50% (vol/vol) PEG 400-20% (vol/vol) ethanol-30% (vol/vol) carboxy-
methylcellulose (0.5% wt/vol in sterile water for injection) or 2% (vol/vol) eth-
anol-5% (wt/vol) dextrose in sterile water for injection. Doses were administered
in volumes of 4 ml/kg, 2 ml/kg, and 1 mg/kg for mice, rats, and cynomolgus
monkeys, respectively. For pharmacokinetic analysis, blood samples were col-
lected from mice via cardiocentesis. Serial blood samples were collected from
rats via a vascular access port located in the lateral saphenous vein. Mice and rats
were euthanized in a CO2 chamber before collection of terminal blood samples
or brain tissue. Serial blood samples from monkeys were collected without
anesthesia via a peripheral vein. Blood samples were collected into polypro-
pylene tubes containing K2EDTA anticoagulant and stored on ice until centri-
fuged for the preparation of plasma. Plasma was stored at 70°C. Whole brains
were collected following decapitation, blotted dry, placed into polypropylene
containers, and then immediately frozen at approximately 70°C. Cerebrospinal
fluid was collected from rats via cisterna magna puncture, placed in sterile
polypropylene tubes, and stored at approximately 70°C.
Brain tissue homogenization. Whole-tissue homogenization of brain tissue
was performed on the day of analysis with either a Precellys 24 bead mill
homogenizer (Bertin Technologies, France) for mouse tissues or an Ultra-Turrax
T25 tissue grinder (IKA-Werke, Wilmington, NC) for rat tissues. Brains were
blotted dry, weighed, and homogenized in 1 volume of PBS. After homogeniza-
tion, an additional single volume of PBS was added to reduce viscosity. Homog-
enization of mouse tissues was performed in 1.5-ml Precellys tubes containing
ceramic CK14 beads (1.4-mm diameter) for 1 cycle, 6.5  103 rpm, for 23 s. Rat
tissues were processed in 15-ml Costar tubes (Corning Inc., Lowell, MA) at
speed setting 4 for 30 s. The density of brain tissue used for the determination of
volume was 1.043 g/ml. All tissue homogenates were treated in a bath sonicator
for 5 min at approximately 22°C to remove air bubbles.
Analysis of test compounds in biological samples. Samples of plasma (25 l)
and cerebrospinal fluid (CSF) (10 l) were treated with 3 volumes of ice-cold
methanol, containing 25 ng/ml of 2-chloro-4-fluoro-N-(1-hydroxy-1,3-
dihyrobenzo[c][1,2]oxaborol-6-yl)benzamide as an internal standard, to precipi-
tate proteins. Homogenates of brain tissue were treated similarly, except that 4
volumes of ice-cold methanol and internal standard solutions were added.
Treated samples were gently mixed at ambient temperature for 10 min and then
centrifuged at approximately 3,000  g for 15 min at 15°C. The supernatants
were transferred to 96-well plates or HPLC vials for analysis by LC-MS/MS,
employing a qualified, two-dimensional chromatographic separation to over-
come ion suppression caused by coelution of endogenous components in brain
tissue with the oxaboroles. In summary, treated samples were loaded onto a
Phenomenex (Torrance, CA) Synergi Polar RP 50- by 2-mm (3-m) extraction
column and then back eluted onto a Phenomenex Luna C8(2) 50- by 2-mm
(3-m) analytical HPLC column. Mobile phases for extraction and analytical
columns comprised 5 mM ammonium formate and 0.1% (vol/vol) formic acid in
deionized water (A) and 5 mM ammonium formate and 0.1% (vol/vol) formic
acid in methanol (B). The samples were loaded onto the extraction column in
40% B and back eluted onto the analytical column using a step gradient to 50%
B between 0.55 to 1.5 min after loading the sample. A linear gradient from 5%
B to 95% B over 4.5 min was employed for analytical chromatography. Test
articles eluted at approximately 3 min. The total run time was 6 min. The
LC-MS/MS instrumentation comprised either a Sciex (Applied Biosystems, Fos-
ter City, CA) API-3000 or API-4000 triple quadrupole mass spectrometer inter-
faced to an Agilent HPLC system via a TurboIonSpray electrospray source
operated in the positive ionization mode. Instrumental conditions and precursors
to product ion transitions for tandem mass spectrometry were optimized for
sensitivity. The MS/MS transitions for AN3520 and SCYX-6759 were 322.1/302.1
and 340.1/191.1 atomic mass units, respectively.
Pharmacokinetic parameters were calculated from composite mean plasma or
tissue data using noncompartmental (oral and intravenous routes) and biexpo-
nential (intravenous route) analyses in Microsoft Excel.
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RESULTS
Structures of study compounds. Oxaborole carboxamides
represent a novel class of lead compounds which exhibit potent
efficacy against T. brucei both in vitro and in vivo. Figure 1
shows the structural formulas of AN3520, SCYX-6759, and
SCYX-9296. Boron, which has thus far been an unexploited
atom in medicinal chemistry, was placed in a benzoxaborole
scaffold containing a fused aromatic ring. SCYX-6759 contains
fluorine meta to the trifluoromethyl group in the pendant
phenyl ring. SCYX-9296 is a direct analogue of AN3520, dif-
fering only in replacement of the B-OH moiety with a car-
bonyl (C 	 O) group.
Inhibition of T. brucei in vitro. Oxaborole carboxamides
AN3520 and SCYX-6759 exhibited potent activity against T. b.
brucei, T. b. rhodesiense, and T. b. gambiense in vitro. Parasite-
mediated reduction of resazurin was used as an indicator of
trypanosome viability. IC50s of approximately 0.04 g/ml and
0.07 g/ml for AN3520 and SCYX-6759, respectively, were
achieved against T. b. brucei (Table 1). Similar IC50s were
attained using T. b. rhodesiense and T. b. gambiense. The MIC
values, defined as the concentration at which no visible growth
of trypanosomes occurred 48 h postexposure to the drug, were
0.08 g/ml and 0.16 g/ml for AN3520 and SCYX-6759, re-
spectively, against T. b. brucei. Additionally, the oxaboroles
exhibited a 90-fold selective inhibition of parasite versus
mammalian cell (L929 mouse cell line) proliferation in vitro
(Table 1).
A parallel series of experiments was done to explore the
possible role of boron in trypanocidal activity. SCYX-9296, a
derivative of AN3520 in which the boron was replaced with a
carbon (Fig. 1), was incubated with T. b. brucei. No inhibition
of trypanosomes was observed when SCYX-9296 was tested in
vitro at concentrations up to 50 g/ml, suggesting that the cyclic
boronic acid is essential for trypanocidal activity.
Time-kill assays and examination of reversibility of effects of
oxaboroles. In order to ascertain a further understanding of
the pharmacokinetic/pharmacodynamic parameters of the in
vitro trypanocidal activity of oxaboroles, time-kill assays (29,
30) were performed using AN3520. The results are presented
in Fig. 2. Trypanosome survival was measured at various times
with continuous drug pressure. The onset of trypanocidal ac-
tivity was very rapid, with IC50s decreasing more than 100-fold
within the first 18 h (Fig. 2B). When measured 24 h after
exposure, the IC50 for AN3520 killing of T. brucei is very close
to that measured in the standard 72-h assay, 0.09 g/ml versus
0.04 g/ml. In summary, the viability of T. brucei exposed to
AN3520 decreased with time and was dependent on a com-
pound concentration up to 0.3 g/ml, or approximately 4 times
the MIC. Overall, there was a 3-log reduction in T. brucei
viability within 24 h following exposure to oxaboroles.
Pulse incubation of T. brucei with AN3520 shows that only a
short period of exposure to the compound is required to pro-
duce irreversible effects on trypanosome survival (Fig. 2C).
Persistency or irreversibility of the oxaborole effect is time and,
to a lesser degree, concentration dependent. As observed for
time-kill experiments, increasing the oxaborole concentration
above 0.3 g/ml did not lead to more robust or faster killing
after washout and incubation in compound-free medium. IC50s
determined following compound washout at various time
points after exposure are displayed in Fig. 2D. SCYX-6759
displayed time-kill and reversibility kinetics that were similar
to those observed with AN3520-treated T. brucei parasites
(data not shown).
Microscopic observations of treated parasites revealed a
clear time-dependent alteration in trypanosome morphology
(see Data S1 in the supplemental material). Within the first 6 h
after exposure, T. brucei parasites exhibited reduced motility.
AN3520-induced changes included gradual loss of shape, re-
sulting in parasites appearing round and reduced in size. This
was accompanied by the appearance of multiple, often elon-
gated or detached flagella. Parasites were completely lysed
within 24 h. Control parasites incubated with the nonboron-
containing analogue SCYX-9296, or medium alone, main-
tained a normal cellular shape and viability throughout the
observation period.
Activity of oxaboroles in murine models of HAT. The poten-
tial in vivo activity of oxaboroles was initially conducted with
the mouse model of acute trypanosomiasis. Female Swiss Web-
ster mice were inoculated intraperitoneally with 2.5  105
parasites of the T. b. brucei EATRO 110 strain. Beginning at
24 h postinfection, the mice were given a twice-daily dose of
either AN3520 or SCYX-6729, at 5 to 10 mg/kg (intraperito-
neal or oral dose) for 4 days. Mice showed 67% or 100% cure
rates, respectively, with no evidence of compound-related tox-
icity (Table 2). Treated animals were monitored weekly for
parasitemia through day 30 postinfection. Animals remaining
parasite free for more than 30 days beyond the end of the
treatment period were considered cured. Untreated animals
succumbed to the disease within 4 to 5 days following infection.
The results of the time-kill assay had demonstrated com-
plete parasite clearance in vitro. To determine whether a single
high dose would produce a similar effect in vivo, T. b. brucei-
infected mice were given a single intraperitoneal dose of
AN3520 at 50 mg/kg at 24, 48, or 72 h postinfection. The single
dose given at 24 or 48 h after inoculation with trypanosomes
resulted in complete cures with mice with acute T. b. brucei
infection. When dosing was delayed until 72 h postinfection,
the cure rate dropped to 30%; however, the animals that suc-
TABLE 1. Activity of oxaborole compounds against T. brucei
subspecies in vitro
Compound
IC50 (g/ml)
T. b. brucei
427
T. b. rhodesiense
STIB900
T. b. gambiense
STIB930 L929
AN3520 0.04 0.038 0.012 3.77
SCYX-6759 0.07 0.038 0.030 9.51
SCYX-9296 50 NDa ND 50
a ND, not determined.
FIG. 1. Structures of AN3520, SCYX-6759, and SCYX-9296.
4382 NARE ET AL. ANTIMICROB. AGENTS CHEMOTHER.
 o
n
 N
ovem
ber 4, 2015 by University of Queensland Library
http://aac.asm
.org/
D
ow
nloaded from
 
cumbed to the disease showed significantly increased survival
times compared to the untreated controls (data not shown).
Successful treatment of stage 2 HAT requires compounds to
cross the BBB and kill T. brucei parasites located within the
CNS. To determine if oxaborole compounds could clear a CNS
infection in mice, animals infected with chronic disease-induc-
ing T. b. brucei TREU 667 strain parasites were dosed intra-
peritoneally or orally with AN3520 or SCYX-6759 (Table 3).
When given at 50 mg/kg twice daily for 7 or 14 days, AN3520
was curative to 71% or 78% of mice, respectively. Cure rates
dropped to 20% or less at doses of 25 mg/kg or less. Cure rates
for SCYX-6759 were 83% and 100%, respectively, for 7 and 14
FIG. 2. Time-kill plots demonstrating concentration-dependent effects and irreversibility of AN3520 in T. b. brucei in vitro. Parasite survival was
measured at various times in the presence of continuous drug pressure (A) or after compound washout at specified times and viability assessment
at 72 h (C). Experiments were conducted in triplicate, and plots represent the mean survival of treated parasites expressed as percentages of the
control, untreated parasites. (B and D) IC50s calculated for time-kill and compound washout procedures, respectively.
TABLE 2. Treatment of T. b. brucei EATRO110 acute mouse
infections with oxaborolesa
Compound Dose(mg/kg) Route
No. of cured
mice/total
no. of mice
Avg. survival
(no. of days) % cured
AN3520 5 p.o. 3/3 30 100
10 p.o. 2/3 11b 67
SCYX-6759 1.25 p.o. 3/5 10.5b 60
2.5 p.o. 5/5 30 100
5 p.o. 3/3 30 100
10 p.o. 3/3 30 100
Diminazene
aceturate
2 i.p. 3/3 30 100
Untreated 0/5 4 0
a Mice were infected with 250,000 T. b. brucei EATRO 110 parasites, and the
infection was allowed to progress for 24 h prior to initiation of treatment.
Parasitemia was examined weekly, and cures were determined as described in
Materials and Methods. Infected animals were dosed twice daily for 4 consecu-
tive days. Diminazene aceturate was administered as a single i.p. dose to serve as
a positive control. Cured animals are defined as those that remained apara-
sitemic for 30 days after the start of the dosing period.
b Average survival of mice showing relapse.
TABLE 3. Treatment of T. b. brucei TREU667 CNS
infections with oxaborolesa
Compound
tested
Dose
(mg/kg)
Dosing
route
Duration
(no. of days)
Avg.
no.
of days
until
relapse
No. of
cured
mice/total
no. of
mice
%
cured
AN3520 50 i.p. 14 52.5 7/9 78
50 i.p. 7 57 12/17 71
25 i.p. 14 51.6 2/10 20
25 i.p. 7 39.1 1/17 6
12.5 i.p. 7 35 0/8 0
SCYX-6759 50 i.p. 14 10/10 100
50 p.o. 7 56 5/6 83
25 p.o. 7 38.8 2/10 20
12.5 p.o. 7 35.7 1/10 10
6 p.o. 7 36.6 1/10 10
Diminazene
aceturate
10 i.p. 1 (D4) 10/10 100
10 i.p. 1 (D21) 48.3 0/10 0
a Mice were infected with 10,000 T. b. brucei TREU667 parasites, and the
infection was allowed to progress for 21 days prior to initiation of treatment.
Parasitemia was examined weekly, and cures were determined as described in
Materials and Methods. Compounds were administered twice daily for 7 or 14
consecutive days. Diminazene aceturate was administered as a single i.p. dose on
day 4 (D4) or day 21 (D21) to serve as positive and negative controls, respec-
tively. Cured animals are defined as those that remained aparasitemic for 180
days after the start of the dosing period.
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days of treatment. Dosing SCYX-6759 at 25 mg/kg or lower did
not provide substantial protection or cure rates in the CNS
model. Diminazene aceturate was also included in the study.
When given early in the infection, prior to CNS involvement,
diminazene aceturate cures the hemolymphatic infection and
prevents the occurrence of a CNS form of the disease in mice
(18, 19). When given at day 21 postinfection, diminazene ace-
turate clears only parasites from peripheral blood, leading to a
CNS disease and reemergence of parasitemia due to the mi-
gration of parasites from the nervous system back into the
vascular and lymphatic system (3, 4, 18, 19). In this study,
diminazene aceturate prevented a CNS infection when given as
a single dose of 10 mg/kg at day 4. In contrast, diminazene
aceturate was unable to resolve the infection when given 21
days after infection (Table 3). Brain homogenates or blood
obtained from AN3520- and SCYX-6759-treated animals that
had survived for more than 180 days after dosing did not
produce an infection when injected into uninfected mice.
Binding to human and mouse plasma proteins and brain
tissue. Binding of AN3520 and SCYX-6759 to human and
mouse plasma proteins was determined by rapid equilibrium
dialysis (RED; Pierce). AN3520 and SCYX-6759 bound exten-
sively to mouse plasma proteins (99.5% and 99.8%, respec-
tively) and more modestly to human proteins (95.3% and
97.7%, respectively). Acceptable mass balances were demon-
strated (97 to 110%).
To assess the possible impact of protein binding on in vitro
potency demonstrated in the assay described above, mouse or
bovine serum was added to the in vitro T. b. brucei inhibition
assay. The resulting in vitro IC50 was attenuated by less than 3-
to 4-fold in the presence of 25% mouse serum or 50% bovine
serum. These results suggest a low affinity for protein binding
(data not shown). In contrast, the in vitro potency of suramin,
the current standard of care for stage 1 HAT (hemolymphatic
stage), when tested under the same conditions, was attenuated
by more than 25-fold.
The binding of AN3520 and SCYX-6759 to mouse brain
tissue was examined over the therapeutically relevant concen-
tration range 0.5 M to 5.0 M. Binding of both compounds
was less extensive to mouse brain tissue than to mouse plasma
proteins and, in contrast to plasma, was generally independent
of concentration (87.6% to 85.3% and 89.6% to 88.6% for 0.5
M to 5.0 M AN3520 and SCYX-6759, respectively). Con-
sequently, it is unlikely that binding to brain tissue would result
in attenuated potency.
AN3520 and SCYX-6759 are low-clearance compounds when
incubated with liver subcellular fractions. Intrinsic clearance
(CLint) and half-life (t1/2) were determined for AN3520 and
SCYX-6759 with human and CD-1 mouse liver microsomes.
The intrinsic clearance value for both compounds was 5
l/min/mg, and half-life was 350 min. AN3520 and SCYX-
6759 were also incubated with mouse, rat, dog, cynomolgus
monkey, and human liver S9 fractions (from males and fe-
males) to evaluate stability against a broader range of phase I
and II cytosolic-metabolizing enzymes. The half-life for both
compounds in liver S9 from all species was 350 min. The
results in liver microsomes and S9 fractions indicate that both
compounds are low-clearance compounds with the potential
for good in vivo pharmacokinetic properties.
Both AN3520 and SCYX-6759 were incubated in freshly
homogenized CD-1 mouse brain tissue. The results suggest
that SCYX-6759 is more stable than AN3520. Following an
incubation of 0.1 M and 5 M of either compound at 37°C for
5 h, 91% and 99%, respectively, of SCYX-6759 remained;
comparatively, only 49% and 68%, respectively, of AN3520
remained at the end of the incubation period.
AN3520 and SCYX-6759 are highly permeable across MD-
CKII-hMDR1 monolayers and are not substrates for P-gp.
MDCKII-hMDR1 cell monolayers were used to assess the in
vitro intrinsic permeability of AN3520 and SCYX-6759 and
whether either could serve as a substrate for P-gp. Cells were
incubated with 3 M of either compound. Mean PappA3B
values for AN3520 and SCYX-6759 of 424 nm/s and 379 nm/s,
respectively, were achieved (Table 4). In an additional exper-
iment, the P-gp modulator GF120918 was included in the in-
cubations (16). AN3520 and SCYX-6759 achieved mean
PappA3BGF918 values of 434 nm/s and 386 nm/s, respectively.
The corresponding absorption quotient (AQ) was 0.02 for both
AN3520 and SCYX-6759, indicating that neither compound
was a substrate for P-gp (an AQ of 0.3 is predictive for P-gp
substrates [41]). The potential for a compound to be readily
permeable across the intestine or BBB is classified as high
when either the PappA3BGF918 is 50 nm/s for the gut (40)
or is 150 nm/s and is a non-P-gp substrate for the BBB (26).
Consequently, the MDCKII-hMDR1 data, complemented
with modest plasma protein binding, predicts that both com-
pounds should cross the BBB. Furthermore, in light of low
metabolic clearance, both compounds should achieve good
systemic exposure following oral administration.
AN3520 and SCYX-6759 present a low risk for CYP450-
based drug-drug interactions. The potential for AN3520 and
SCYX-6759 to exert drug-drug interactions mediated through
inhibition of cytochrome P450 activities was assessed using the
P450-Glo assay (Promega) for recombinant human CYP450
isoforms 3A4, 1A2, 2C19, 2C9, and 2D6 (Table 5). The poten-
TABLE 4. MDCKII-hMDR1 permeability
Compound
Papp
A3B
(nm/s)
Papp
A3
BGF918
(nm/s)
Mass balance
(%) Absorption
quotient
P-gp
classification
A3B A3BGF918
AN3520 424 434 92 90 0.02 Nonsubstrate
SCYX-6759 379 386 89 95 0.02 Nonsubstrate
TABLE 5. Potential for AN3520 and SCYX-6759 to inhibit
cytochrome P450 enzyme activities
CYP isoform
IC50 (M)a
AN3520 SCYX-6759
3A4 100 100
2D6 38.7 30.3
2C9 29.6 30.6
2C19 69.7 47.4
1A2 100 100
a The potential of drug-drug interactions was classified as high (IC50  1 M),
moderate (1 M  IC50  10 M), or low (IC50  10 M), according to the
observed level of enzyme inhibition. The values are expressed as the means from
triplicate determinations.
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tial for drug-drug interactions can be quantified as high
(IC50  1 M), moderate (1 M  IC50  10 M), or low
(IC50  10 M) according to the observed level of enzyme
inhibition (24). Both AN3520 and SCYX-6759 exhibited IC50s
that were 10 M for all CYP isoforms studied, indicating a
low potential for CYP450-based adverse drug-drug interac-
tions.
Pharmacokinetics following single intravenous and oral ad-
ministration to rodents and primates. Tables 6 and 7 present
summaries of the values of the pharmacokinetic parameters
determined following the administration of single doses of
SCYX-6759 and AN3520 by either an intravenous or oral
route. Plasma, rather than whole blood, was selected for the
studies because of the limited distribution of AN3520 in eryth-
rocytes (data not shown). Analysis of plasma concentration was
considered to be more pharmacologically relevant for the sys-
temic clearance of parasites.
Following intravenous administration of 2 mg/kg to mice,
AN3520 demonstrated an apparent elimination half-life of
2.9 h, a systemic clearance value (CL) of 0.12 liters/h/kg, and a
volume of distribution (V) of 0.47 liters/kg (Table 6). Compar-
atively, SCYX-6759 achieved a superior pharmacokinetic pro-
file, most notably an extended t1/2 of 11.4 h, a lower systemic
clearance of 0.06 liters/h/kg, and a V of 0.97. In light of these
results, the decision was made to advance SCYX-6759 for
evaluation in Sprague-Dawley rats and cynomolgus monkeys.
In rats, following intravenous administration of 13.4 mg/kg of
SCYX-6759, an apparent elimination t1/2 value of 13.8 h was
achieved, along with a systemic clearance value of 0.37 liters/
h/kg and a V value of 4.61. Intravenous administration of
SCYX-6759 of 2 mg/kg in cynomolgus monkeys resulted in an
apparent elimination t1/2 value of 8.8 h, a systemic clearance
value of 0.104 liters/h/kg, and a V value of 0.741 liters/kg.
Systemic clearance was low in both species, approaching 5% of
hepatic blood flow (15). Values for the volume of distribution
were low in mice and monkeys, suggesting that the compounds
remained in the plasma compartment rather than concentrat-
ing in tissues; surprisingly, V appeared markedly higher in rats.
Following oral administration, both AN3520 and SCYX-
6759 were absorbed rapidly into the systemic circulation (Table
7). Maximum blood concentrations (Cmax) were observed at
approximately 10 min (AN3520) and 30 min (SCYX-6759) in
rodents. Maximum blood concentrations were observed at
1.3 h in monkeys (SCYX-6759 only). After a single 8.2-mg/kg
dose in mice, AN3520 demonstrated an apparent elimination
t1/2 value of 3.7 h and an oral clearance (CL/F) value of 0.29
liters/h/kg. SCYX-6759 was administered to mice at dose levels
of 9, 20.8, or 29.2 mg/kg. The values for the apparent elimina-
tion t1/2 were 20.2, 17.1, and 18.2 h, respective of dose level;
oral clearance (CL/F) values of 0.093, 0.230, and 0.219 liters/
h/kg were achieved. Exposure generally increased with dose.
Notably, a comparison of SCYX-6759 and AN3520 reveals that
following a 9-mg/kg dose of SCYX-6759, the oral clearance of
SCYX-6759 (0.093 liters/h/kg) was approximately a 3-fold im-
provement over the value achieved for AN3520 (0.289 liters/
h/kg).
In rats, following administration of a single oral dose of
SCYX-6759 at levels of 13.4, 23.5, or 50.2 mg/kg, the values of
maximum blood concentrations (Cmax) increased in direct pro-
portion to dose. The area under the concentration-time curve
to infinity (AUC0–
) increased in a less-than-proportional
manner. The median oral clearance rates in rats for dose levels
13.4, 23.4, and 50.2 mg/kg were 0.117, 0.216, and 0.334 liters/
h/kg, respectively. The values attained for the apparent elimi-
nation t1/2 were 8.1 and 5.4 h. Absolute bioavailability for
SCYX-6759 was excellent, with values of 90% and 123%.
TABLE 6. Pharmacokinetic parameters for AN3520 and SCYX-6759 in male CD-1 mice, male Sprague-Dawley rats, and male nonnaı¨ve
cynomolgus monkeys in plasma, following intravenous administration
Animal Compound Dose (mg/kg) AUC03last (g  h/ml) tlast (h) AUC03
 (g  h/ml) CL (liters/h/kg) V (liters/kg) t1/2 (h)
Mouse AN3520 2 17.95 16 18.1 0.1115 0.4745 2.875
SCYX-6759 3.3 44.7 24 56.4 0.059 0.97 11.4
Rat SCYX-6759 13.4 26.4 18 26.4 0.371 4.61 13.8
Monkey SCYX-6759 2 20.1 48 20.3 0.104 0.741 8.8
TABLE 7. Pharmacokinetic parameters for AN3520 and SCYX-6759 in male CD-1 mice, male Sprague-Dawley rats, and male nonnaı¨ve
cynomolgus monkeys in plasma following oral administrationa
Species Compound Dose (mg/kg) AUC03last(g  h/ml) tlast (h)
AUC03

(g  hrml) CL/F (liters/h/kg) t1/2 (h) Tmax (h) Cmax (g/ml) F (%)
Mouse AN3520 8.2 28.42 24 28.7 0.289 3.67 0.17 4.35 39
SCYX-6759 9 56.9 24 96.3 0.093 20.2 0.5 5.3 69
20.8 58.7 24 90.4 0.23 17.1 0.5 8.3 54
29.2 86.6 24 133 0.219 18.2 0.5 19.2 54
Rat SCYX-6759 13.4 49.6 18 ND ND ND 2 6.28 ND
23.5 92.4 12 95.5 0.261 8.1 2 11.6 123
50.2 132 12 150 0.334 5.4 1 21.1 90
Monkey SCYX-6759 10 84.4 48 85.6 0.125 9 1.3 12.3 85.6
a Tmax, time to maximum concentration of drug in serum; Cmax, maximum concentration of drug in serum; ND, not determined (the elimination phase could not be
determined; consequently, there are no values for t1/2 or F).
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Oral administration of a single dose of SCYX-6759 in non-
naïve cynomolgus monkeys at a dose level of 10 mg/kg attained
84% bioavailability, as well as an apparent elimination half-life
of 9 h, similar to that observed in rats. Oral clearance (CL/F)
of 0.125 liters/h/kg was obtained, a modest 2-fold improvement
over that obtained in rats. A maximum blood concentration
(Cmax) of 12.3 g/ml was achieved at 1.3 h. The AUC0–
 was
calculated as 85.6 g  h/ml, a 2- to 3-fold increase in the
AUC0–
 observed in rats (based on normalizing doses to 10
mg/kg).
Pharmacokinetic parameters in brain tissue and CSF were
evaluated in male Sprague-Dawley rats after oral administra-
tion of 13.4, 23.5, and 50.2 mg/kg (Table 8). Values for the
brain/plasma ratio based on the area under the concentration-
time curve from 0 minutes postdose to the concentration of the
last quantifiable time point (AUC0–last) were between 8% and
20% for the low (13.4 mg/kg)- and high (50.2 mg/kg)-dose
groups, respectively. The corresponding brain/plasma ratios,
based on Cmax, were between 16% and 26%. SCYX-6759 also
partitioned into CSF, achieving CSF/brain ratios between 24%
and 49% based on AUC0–last and between 22% and 49% based
on Cmax.
Pharmacokinetics following repeat oral administration to
infected mice. The impact of exposure in plasma and brain
compartments on efficacy in a murine model of stage 2 (CNS)
HAT was determined by dosing an additional group of infected
mice with the same regimen as that of infected animals under-
going treatment with SCYX-6759. Infected female Swiss Web-
ster mice received SCYX-6759 as a twice-daily (q12h) oral
dose for 7 days. Dose levels were 6, 12.5, 25, and 50 mg/kg.
Blood samples and complete brain tissues were harvested from
the animals after the last dose on study day 7. Remaining
infected animals were monitored for recurrence of para-
sitemia, as described in Materials and Methods.
Concentration versus time profiles and pharmacokinetic pa-
rameters are presented in Fig. 3 and Table 9. SCYX-6759
demonstrated increases in Cmax and AUC0–last in plasma and
whole-brain tissue in a generally dose-dependent manner. The
average plasma concentrations at steady state were determined
from the AUC0–last. The results show that even for the animals
in the low-dose group (6 mg/kg), plasma concentrations of
SCYX-6759 were approximately 25-fold more than the in vitro
MIC. This concentration of compound is considered to be at a
level sufficient to clear blood-borne parasites. Values for the
brain/plasma ratio based on AUC0–last were between approxi-
mately 6% and 27% for the low (6 mg/kg)- and high (50
mg/kg)-dose groups, respectively. The corresponding brain/
plasma ratios based on Cmax were between 16% and 47% for
the low (6 mg/kg)- and high (50 mg/kg)-dose groups, respec-
tively. Exposure in brain exceeded the in vitro MIC only in
animals receiving 50 mg/kg SCYX-6759.
DISCUSSION
Current treatment regimens for HAT are comprised of 4
drugs: pentamidine, suramin, melarsoprol, or eflornithine, and
the combination nifurtimox-eflornithine. These drugs are toxic
and cumbersome in their administration (44). The need for a
safe, effective, easily administered treatment is critical, with
over 60 million people at risk for HAT in sub-Saharan Africa.
SCYX-6759 and AN3520 belong to a novel class of boron-
containing compounds which are potent inhibitors of T. brucei.
Boron is an unexploited atom in medicinal chemistry. The
utility of boron has been recently highlighted with the devel-
opment of new antifungal, antibacterial, and anti-inflammatory
compounds (2, 6, 7, 9), some of which are currently undergoing
TABLE 8. Pharmacokinetic parameters for SCYX-6759 in male
Sprague-Dawley rats in brain and CSF
following oral administration
Matrix Dose(mg/kg)
AUC03last
(g  h/ml)
tlast
(h)
AUC03

(g  h/ml)
t1/2
(h)
Tmax
(h)
Cmax
(g/m)
Brain 13.4 4.1 12 4.4 6 1 0.99
23.5 11.9 18 11.9 2.6 2 2.32
50.2 26.8 12 27.2 2.9 2 5.5
CSF 13.4 2.02 12 2.02 4.6 1 0.364
23.5 3.61 12 3.65 3.1 4 1.13
50.2 6.33 12 6.33 2.5 6 1.22
FIG. 3. Concentration-time profiles for SCYX-6759 in plasma
(solid lines) or whole brain tissue (broken lines) from infected female
Swiss Webster mice receiving either 6 mg/kg (open diamond), 12.5
mg/kg (vertical open rectangle), 25 mg/kg (horizontal open rectangle),
or 50 mg/kg (open circle) oral doses of SCYX-6759, twice daily (q12h)
for 7 days. The horizontal broken line represents the in vitro MIC.
Plasma and brain data are presented as either micrograms per milli-
liter or micrograms per gram of wet tissue, respectively.
TABLE 9. Pharmacokinetic parameters for SCYX-6759 in plasma
and brain tissue of infected female Swiss Webster micea
SCYX-6759 in: Dose(mg/kg)
Cmax
(g/ml)
Cmin
(g/ml)
AUC0312 h
(g  h/ml) t1/2
Plasma 6 6.1 3.65 57 10.8
12.5 7.1 3.20 55 11.6
25 8.1 5.50 74 14.7
50 17.5 5.80 101 11.6
Complete brain
tissue
6 1.0 0.06 3.3 3.4
12.5 1.6 0.05 4.8 3.4
25 3.6 0.10 13.6 2.0
50 8.3 0.26 27.5 2.5
a Infected female Swiss Webster mice received 6, 12.5, 25, or 50 mg/kg oral
doses of SCYX-6759, twice daily (q12h) over 7 days.
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clinical trials (1, 37). Replacement of the boron atom with
carbon (SCYX-9296) results in the loss of trypanocidal activity.
Recent studies show that boron and the oxaborole ring are
required for the inhibition of yeast cytoplasmic leucyl-tRNA
synthetase by 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxabo-
role (AN2690) (37). Conversely, replacement of the boron
atom of the peptide boronate Z-Leu-Leu-Leu-B(OH)2 proteo-
some inhibitor (or other related boronic acids, such as Vel-
cade) shows a modest impact on trypanocidal activity in vitro
(31). This suggests that the two classes of boron-containing
compounds have different mechanisms of action and poten-
tially different clinical profiles.
The antitrypanosomal activities of AN3520 and SCYX-6759
were examined via time-kill studies. Both compounds yielded a
concentration- and time-dependent decrease in ATP content.
These data suggest that oxaboroles are primarily time-dependent
trypanocidal agents whose efficacy is only partly dependent on
concentration. Limited studies have been conducted in the past to
investigate the time-kill kinetics of trypanocidal agents in vitro to
generate models for the evaluation of the activity of compounds
for the treatment of HAT. One such example demonstrated T.
brucei killing in vitro by pentamidine to be both time and concen-
tration dependent, but several days were required to see this
trend, even at concentrations far in excess of the MIC (28). In
contrast, time-kill kinetics of antibacterial agents have been ex-
plored extensively against a variety of bacterial pathogens. Based
on such studies, the killing action of antibacterial agents has been
classified as being dependent either on exposure (maximum con-
centration/MIC), the area under the concentration-time curve/
MIC, or simply the time that the antibiotic concentration is kept
above the MIC (29, 30). Antibacterial agents are generally clas-
sified as cidal when they produce a 3-log reduction in bacterial
viability after exposure to the test agent, a result observed with
both oxaborole compounds in this study.
The potential for the reversibility of trypanocidal effects
revealed that exposure of T. brucei to oxaborole compounds at
concentrations 5- to 10-fold above MICs for 8 to 12 h results in
elimination of parasites from culture, even after the com-
pounds have been washed away. The inability of T. brucei
parasites to recover from transient exposure to compounds in
vitro suggests that oxaboroles are retained within the parasites
or that they exert irreversible effects on the potential target(s)
within the parasite during this time frame. This early “com-
mitment to death” phenomenon has implications for in vivo
efficacy, as it suggests that serum concentrations above the
MIC do not need to be maintained for extended periods of
time to achieve cure or parasite elimination. The “commitment
to death” phenomenon following a short exposure has been
reported for trypanosome killing by diminazene aceturate, try-
bizine hydrochloride, or S-adenosylmethionine decarboxylase
inhibitors, but much higher IC50/MIC ratios were used and
extended periods were required to observe full suppression of
parasite growth (3, 20, 21). We have classified oxaboroles as
cidal agents against T. brucei because they demonstrated a
greater-than-3-log reduction in parasite viability over a 24-h
period with no evidence of visible growth of organisms after
this period. Animals infected with T. b. brucei and treated twice
daily, either intraperitoneally or orally for 4 days, were cured at
rates of 67% to 100%. These preliminary results indicated that
the use of oxaboroles for the treatment of HAT was tenable
and merited further study.
Metabolism and pharmacokinetic studies revealed that
SCYX-6759 and AN3520 are low-clearance compounds (5
l/min/mg) with a long half-life in vitro (350 min), as dem-
onstrated during incubations with liver microsomal or S9 sub-
cellular fractions from multiple animal species. Concordant
with the in vitro metabolic stability data, both compounds
achieved low clearance, approaching only 5% of liver blood
flow when administered to mice. SCYX-6759 was advanced to
further pharmacokinetic studies in rats and nonhuman pri-
mates, where it maintained intravenous clearance values below
5% of liver blood flow. Inhibition studies with recombinant
human CYP450 enzymes afforded IC50s greater than 10 M
for all isoforms studied, indicative of a low risk for metabolism-
based drug-drug interactions.
SCYX-6759 and AN3520 were well absorbed following oral
administration in multiple animal species. SCYX-6759 ap-
peared to achieve marginally higher bioavailability. Both ox-
aborole compounds demonstrate propensity to cross the
blood-brain barrier, as revealed in results from a transport
assay predicative for non-P-gp substrates (absorption quotient
less than 0.3) (26). Each compound exceeded the predicative
value by 2.5-fold. The capacity of SCYX-6759 and AN3520 for
intestinal permeability was shown to be 7-fold greater than the
threshold value of 50 nm/s (40).
While the in vitro potency against T. b. brucei was similar for
both compounds (Table 1) and both achieved complete cures
in the murine hemolymphatic model of HAT (Table 2), our
studies revealed that SCYX-6759 possessed superior pharma-
cokinetics. These were beneficial in the stage 2 (CNS) murine
HAT model where, in contrast to AN3520, SCYX-6759 was
able to achieve complete cures following a twice-daily intra-
peritoneal treatment with 50-mg/kg doses (a 100% cure for
SCYX-6759 versus a 78% cure for AN3520). Cure rates were
also modestly superior for SCYX-6759 following oral delivery
(Table 3). For SCYX-6759, this was associated with mainte-
nance of a whole-brain concentration (Fig. 3) above the in vitro
MIC (0.156 g/ml). The importance of sustained exposure to
oxaborole concentrations above the MIC for efficacy is consis-
tent with time-kill data.
Exposure in rodent brain tissue increased with dose. This is
consistent with saturation of an efflux transporter at the blood-
brain barrier or saturation of plasma protein binding. Binding
to proteins, despite being approximately 99% in mice, ap-
peared to be low affinity, because the addition of 50% serum
only attenuated potency in the in vitro T. b. brucei assay by 2-
to 3-fold. In contrast, the in vitro potency of suramin, the
current standard-of-care medication for hemolymphatic HAT,
was attenuated by more than 25-fold under similar conditions.
Interestingly, binding to brain tissue was less extensive than to
plasma proteins, suggesting brain levels of these highly perme-
able compounds may be greatly influenced by clearance of free
drug from plasma. In vitro biodistribution and in vitro trans-
porter studies are under way to provide further insight (39).
In summary, we have identified a class of boron-contain-
ing compounds, oxaborole carboxamides, as novel leads with
potent and selective activity against T. brucei. Oxaboroles
display rapid time-dependent killing of parasites and dem-
onstrate efficacy against T. brucei in murine models of acute
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and chronic infections. Pharmacokinetic analysis in rodent
and primate models shows that oxaboroles are highly bio-
available and readily cross the blood-brain barrier to ac-
count for their efficacy against late-stage HAT. The anti-
parasitic and pharmacological profiles of oxaborole
carboxamides provide a unique opportunity for the devel-
opment of safe and effective treatments that could serve as
key tools for the eradication of sleeping sickness as a major
public health issue in sub-Saharan Africa.
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